Habib El-Khoury
Overview
Explore the profile of Habib El-Khoury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nadeem O, Aranha M, Redd R, Timonian M, Magidson S, Lightbody E, et al.
Nat Commun
. 2025 Jan;
16(1):358.
PMID: 39753553
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase...
2.
Bertamini L, Alberge J, Lee D, Lee D, El-Khoury H, Kim S, et al.
Blood
. 2024 Nov;
145(8):840-849.
PMID: 39571144
Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We...
3.
Nadeem O, Aranha M, Redd R, Timonian M, Magidson S, Lightbody E, et al.
medRxiv
. 2024 May;
PMID: 38699307
Background: Early therapeutic intervention in high-risk SMM (HR-SMM) has demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets and quadruplet studies have been examined in this same...
4.
Lee D, El-Khoury H, Tramontano A, Alberge J, Perry J, Davis M, et al.
Blood Adv
. 2024 Jan;
8(7):1737-1746.
PMID: 38212245
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) for the detection of MGUS has...
5.
Mouhieddine T, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2560-2571.
PMID: 38019104
Significance: Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and...
6.
Cowan A, Ferrari F, Freeman S, Redd R, El-Khoury H, Perry J, et al.
Lancet Haematol
. 2023 Mar;
10(3):e203-e212.
PMID: 36858677
Background: Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the basis of monoclonal protein concentrations or bone marrow...
7.
Boiarsky R, Haradhvala N, Alberge J, Sklavenitis-Pistofidis R, Mouhieddine T, Zavidij O, et al.
Nat Commun
. 2022 Nov;
13(1):7040.
PMID: 36396631
Multiple myeloma is a plasma cell malignancy almost always preceded by precursor conditions, but low tumor burden of these early stages has hindered the study of their molecular programs through...
8.
Nassar A, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl E, et al.
Cancer Cell
. 2022 Sep;
40(10):1161-1172.e5.
PMID: 36179682
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the extent to which TMB-high generalizes...
9.
El-Khoury H, Lee D, Alberge J, Redd R, Cea-Curry C, Perry J, et al.
Lancet Haematol
. 2022 Mar;
9(5):e340-e349.
PMID: 35344689
Background: Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3%...
10.
Tahri S, Mouhieddine T, Redd R, Lampe L, Nilsson K, El-Khoury H, et al.
Blood Adv
. 2021 Nov;
6(7):2230-2235.
PMID: 34847227
Clonal hematopoiesis (CH) is associated with adverse outcomes in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma undergoing autologous stem cell transplantation. Still, its implications for patients with indolent NHL...